GE and Lilly to collaborate on cancer drug analysis
GE Healthcare, through its GE Global Research division headquartered in Niskayuna, in the USA, is to collaborate with US drug major Eli Lilly on the development of ways to predict responses to various cancer treatments.
During the collaboration, terms of which were not disclosed, Lilly will provide its cancer drug expertise and anonymous tissue samples from patients involved in cancer drug trials for use in GE's development of image analysis tools capable of identifying therapeutic effects. Richard Gaynor, Eli Lilly's vice president of cancer research and global oncology, said that the deal would focus on "finding the right dose of the right medication at the right time."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze